News & Events

ZS Pharma Submits New Drug Application to U.S. Food and Drug Administration for ZS-9 for the Treatment of Hyperkalemia

Redwood City, Calif. – May 26, 2015 – ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for ZS-9 (sodium zirconium cyclosilicate). The NDA requests FDA approval of ZS-9 for the treatment of hyperkalemia. “The submission of the NDA for ZS-9 is a major...

read more

Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update

SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today reported financial results for the quarter ended March 31, 2015 and provided an update on its corporate activities and product pipeline. First Quarter 2015 and Subsequent Highlights Filed New Drug Application (NDA) with FDA for AuriProTM: On February 25, 2015, Otonomy submitted an NDA to...

read more

ZS Pharma Reports First Quarter 2015 Financial Results and Provides ZS-9 Program Update

ZS Pharma Reports First Quarter 2015 Financial Results and Provides ZS-9 Program Update   Redwood City, Calif. – May 11, 2015 – ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company’s investigational treatment for hyperkalemia, and reported its financial results for the first quarter ended...

read more

Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has completed enrollment in a Phase 2 clinical trial evaluating AuriPro™, a sustained-exposure formulation of the antibiotic ciprofloxacin, for the treatment of pediatric patients with acute otitis media with tympanostomy tubes (AOMT). “We are very encouraged by the...

read more

RiverVest Venture Partners Closes on $80 Million Life Sciences Fund

RiverVest Venture Partners Closes on $80 Million Life Sciences Fund ST. LOUIS, MO (May 5, 2015) – Life sciences venture capital firm RiverVest Venture Partners today announced the final closing of RiverVest Venture Fund III, L.P. at $80.2 million. “This is a great time to be investing in drugs and therapeutic medical devices,” said RiverVest Managing Director Jay Schmelter. “There are many attractively valued investment opportunities in our space right now.” Since its initial closing last year, RiverVest Venture Fund III has made...

read more

Otonomy Announces FDA Acceptance of AuriPro(TM) New Drug Application

SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that its New Drug Application (NDA) for the approval of AuriProTM as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the...

read more

Otonomy to Present AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference

SAN DIEGO, April 21, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that previously reported results from two Phase 3 trials evaluating AuriPro™ in pediatric patients with middle ear effusion undergoing tympanostomy tube placement surgery will be presented in a podium presentation at the 2015 American Society of Pediatric Otolaryngology...

read more

Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere’s Disease Patients

SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it has achieved target enrollment in its multiple-dose safety study of OTO-104 in patients with Ménière’s disease. This prospective, randomized, placebo-controlled study, designed to evaluate the safety of quarterly dosing of OTO-104, enrolled a total of 128...

read more

Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Label Expansion Indication

AuriPro to be Evaluated in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the enrollment of the first patients in a Phase 2 clinical trial evaluating AuriProTM for the treatment of pediatric patients with acute otitis media with tympanostomy tubes (AOMT). A...

read more

ZS Pharma Announces Upsizing and Pricing of $186 Million Public Offering of Common Stock

REDWOOD CITY, Calif., March 25, 2015 (GLOBE NEWSWIRE) — ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced the upsizing and pricing of its underwritten public offering. The size of the offering has been increased from the previously announced 3,300,000 shares of common stock to 4,015,939 shares of common stock. The shares are being offered to the public at a price...

read more